Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Drug Resistance
100%
Five Cells
100%
Chemoresistance
100%
Human Ovarian Carcinoma
100%
Tumor Cells
75%
Topos
75%
Resistant Cells
50%
Taxol
50%
Drug Resistance Mechanisms
50%
Resistance Genes
50%
Human Ovarian Cancer
50%
Multidrug Resistance Protein 1 (MDR1)
50%
New Drugs
25%
P53 Expression
25%
IC50 Value
25%
Biochemical Mechanism
25%
Cross-resistance
25%
Effective Compounds
25%
Genetic Mechanism
25%
Ovarian Cancer
25%
Cisplatin Resistance
25%
Biological Characteristics
25%
Resistance Development
25%
As(III)
25%
Alpha Expressions
25%
Biochemical Characteristics
25%
Cell Cycle Distribution
25%
Taxol Resistance
25%
Low-density Lipoprotein Receptor-related protein-1 (LRP1)
25%
Clinical Development
25%
Carboplatin Resistance
25%
Platinum Agents
25%
Drug-resistant Tumor
25%
Proliferation Rate
25%
Human Ovarian Carcinoma Cells
25%
Platinum-based Therapy
25%
Taxol/paclitaxel
25%
Intracellular Drug Accumulation
25%
Carboplatin/paclitaxel
25%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
100%
Drug Resistance
100%
Paclitaxel
62%
Neoplasm
37%
Ovary Cancer
37%
Carboplatin
25%
Cisplatin
25%
Platinum
25%
Protein P53
12%
IC50
12%
Cross-Resistance
12%
Immunology and Microbiology
Drug Resistance
100%
Tumor Cell
37%
Cell Cycle
12%
P53
12%
Cross-Resistance
12%
Carcinoma Cell
12%
IC50
12%
Drug Accumulation
12%
Biochemistry, Genetics and Molecular Biology
Drug Resistance
100%
Cisplatin
25%
Cell Cycle
12%
P53
12%
Biochemical Mechanism
12%
Cross Resistance
12%
IC50
12%
Genetic Mechanism
12%
Drug Accumulation
12%